- Home
- KRC vs ACLX Comparison
KRC vs ACLX Comparison
Compare KRC & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$39.10
N/A
Current Price
$64.70
Company Overview
Basic Information| Metric | KRC | ACLX |
|---|---|---|
| Founded | 1947 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.2B |
| IPO Year | 1997 | 2022 |
Fundamental Metrics
Financial Performance| Metric | KRC | ACLX |
|---|---|---|
| Price | $39.10 | $64.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | $41.75 | ★ $115.71 |
| AVG Volume (30 Days) | 1.3M | ★ 1.5M |
| Earning Date | 10-27-2025 | 11-05-2025 |
| Dividend Yield | ★ 5.44% | N/A |
| EPS Growth | ★ 62.23 | N/A |
| EPS | ★ 2.71 | N/A |
| Revenue | ★ $1,126,859,000.00 | $35,898,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.41 | $302.49 |
| P/E Ratio | $14.66 | ★ N/A |
| Revenue Growth | ★ 0.77 | N/A |
| 52 Week Low | $27.07 | $47.86 |
| 52 Week High | $45.03 | $94.07 |
Technical Indicators
Market Signals| Indicator | KRC | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 30.52 | 31.49 |
| Support Level | $39.58 | $68.64 |
| Resistance Level | $41.01 | $73.98 |
| Average True Range (ATR) | 0.99 | 4.47 |
| MACD | -0.23 | -0.48 |
| Stochastic Oscillator | 0.00 | 1.20 |
Price Performance
Historical Comparison KRC
ACLX
About KRC Kilroy Realty Corporation
Kilroy Realty is a premier owner and landlord of approximately 17 million square feet of office space across Los Angeles, San Diego, the San Francisco Bay Area, Austin, Texas, and greater Seattle. The company operates as a real estate investment trust.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.